Protective Effect of Estrogen (E2) and Increased Risk of E2 Plus Progestin (Prog) on Breast Cancer (BrCa). The 2009 Review of the Women's Health Initiative (WHI) Hormone Replacement Therapy (HRT) Published Trials
| Autor: | Joseph Ragaz, John J. Spinelli, J Budlovsky, Nhu D. Le |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Gynecology
Oncology Cancer Research medicine.medical_specialty business.industry Women's Health Initiative medicine.medical_treatment Hazard ratio Oophorectomy Hormone replacement therapy (menopause) medicine.disease Placebo Breast cancer Internal medicine medicine Breast disease business Tamoxifen medicine.drug |
| Zdroj: | Cancer Research. 69:908-908 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | INTRODUCTION & METHODOLOGY.The objective of this review is to identify from the two WHI published randomized HRT trials the BrCa risk or benefit, with a special focus on different impact of E2-alone vs E2+Prog on human breast carcinogenesis (BrCa-genesis).In the 1st trial (JAMA 2002, 2007), healthy women age 50 - 79 were randomized to E2 plus Prog versus placebo (Plac). Reviewed were Hazard ratios (HRs) for all pts and also for those with or without prior Hormone use. Mean follow up was 5.2 years.In the 2nd trial (JAMA 2004, 2006), women with hysterectomy age 50 - 79 were randomized to E2 alone (without Prog) versus Plac. Mean follow up was 7.1 years. Reviewed were all pts, and also subsets with or without prior E2 or Prog; with or without prior history of Benign Breast Disease (PHBrD); and with or without prior history of a 1st degree relative with BrCa (PH1stRelBrCa).RESULTS.Invasive BrCa incidence:N (%)HR95% C.I.1st TrialAll participants:16,608 (100%)1.260.83 - 1.97No prior Hormone use:12,304 (74.1%)1.060.81 - 1.38Prior Hormone use Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 908. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|